Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event
NKI-RIF1
1 other identifier
observational
300
1 country
2
Brief Summary
This study is designed to evaluate the use of a collection of tests that measure the eye response, balance, oculomotor and reaction time tests to aid in the diagnosis of mTBI. The tests use highly precise measurement tools to assess various neurologic functions. (For example, high-speed cameras to record eye movement, high-end motors to precisely spin and move the subject, comprehensive analysis to stitch together the stimulus and the response.) Hypotheses:
- 1.A battery of oculomotor, vestibular and reaction time tests will generate variables that when properly weighted and run through a given multi-variant analysis, will separate the subjects into one of two groups, mTBI or not-mTBI.
- 2.A battery of neurologic assessment tests including reaction time, vestibular and oculomotor tests taxing a range of neurologic functions and executed using one or more of the I-Portal® family of devices, will generate responses that, when used by a trained physician, can aid in the diagnosis of an mTBI.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2013
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 10, 2013
CompletedFirst Posted
Study publicly available on registry
April 16, 2013
CompletedStudy Start
First participant enrolled
September 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2015
CompletedJuly 19, 2019
July 1, 2019
1.9 years
April 10, 2013
July 16, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Variability of latency in reflexive saccades (ms)
Examine the latency of subjects with mTBI with respect to mean latency and standard deviation of control subjects.
within 7 days of a concussion event
Variability of latency in reaction time test (ms)
Examine the latency of subjects with mTBI with respect to mean latency and standard deviation of control subjects.
within 7 days of a concussion event
Variability of error in subjective visual vertical test (degrees)
Examine the mean error of subjects with mTBI with respect to mean error and standard deviation of control subjects.
within 7 days of a concussion event
Study Arms (2)
mTBI
Subjects who undergo an mTBI event
Control
Subjects who do not undergo an mTBI
Eligibility Criteria
The Investigational Group includes Service Members (SM) and civilians who had been diagnosed with an mTBI. The Control Group consists of SM and civilians who do not have clinical symptoms consistent with mTBI. There will be at least 90 participants in each group, for a target total of at least 180 study participants.
You may qualify if:
- \- Diagnosed with traumatic brain injury utilizing 2007 DoD Standard diagnosis of
- \) Exposed to an event,
- \) Suffered alteration or loss of consciousness secondary to the event, and
- \) Had a sequelae from the event.
You may not qualify if:
- Brain injury resulting from a penetrating wound to the head, neck, face or brain (to include gunshot wounds)
- Presence of severe aphasia
- Persons whom have had an mTBI within the prior month and are symptomatic.
- Persons with a previous history of multiple mTBIs and are symptomatic.
- History of neuropsychiatric disorders antedating the head injury (e.g. hypochondriasis, major depression, schizophrenia)
- Pregnancy
- Prior disorders of hearing and balance including:
- Meniere's disease
- Chronic migraine
- Multiple sclerosis
- Vestibular neuritis
- Vestibular schwannoma
- Sudden sensorineural hearing loss
- Cerebrovascular disorders
- Systemic disorders: e.g. chronic renal failure, cirrhosis of the liver, etc.
- +4 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Neurolignlead
- United States Department of Defensecollaborator
Study Sites (2)
Naval Medical Center San Diego
San Diego, California, 92134, United States
Madigan Army Medical Center
Tacoma, Washington, 98431, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alex Kiderman, PhD ME
Neuro Kinetics, Inc
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 10, 2013
First Posted
April 16, 2013
Study Start
September 1, 2013
Primary Completion
August 1, 2015
Study Completion
November 1, 2015
Last Updated
July 19, 2019
Record last verified: 2019-07